Mathieu Lepage

Title: Innovations by Inventor Mathieu Lepage

Introduction

Mathieu Lepage is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of medical research, particularly in the development of compounds targeting prostate-specific membrane antigen (PSMA). His work is crucial for advancing treatments for prostate cancer.

Latest Patents

Lepage holds a patent for 18/19F-labelled compounds which target the prostate-specific membrane antigen. This patent discloses novel compounds comprising a zwitterionic trifluoroborate prosthetic group that specifically target PSMA, which is vital in the context of prostate cancer. The compounds have a specific formula where each R1 is an anionic group, L is a linker, and R2B-F3 is —N(R)CHBF, a pyridinium group substituted with BFor methyl BF, or an azole group substituted with methyl BF3. The patent also outlines methods and uses for imaging and treating PSMA-expressing cancers.

Career Highlights

Throughout his career, Mathieu Lepage has worked with esteemed institutions such as the British Columbia Cancer Agency Branch and The University of British Columbia. His experience in these organizations has allowed him to contribute significantly to cancer research and treatment methodologies.

Collaborations

Lepage has collaborated with Kuo-shyan Lin, enhancing the research and development of innovative cancer treatments.

Conclusion

Mathieu Lepage's work in developing targeted compounds for prostate cancer represents a significant advancement in medical research. His contributions are vital for improving treatment options for patients suffering from this disease.